Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →ML Fraud Detection Score: 83%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
8,817
Total Claims
$394K
Drug Cost
1,131
Beneficiaries
$348
Cost/Patient
Risk Score Breakdown 21/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+324%
Opioid rate vs peers
9.5% vs 2.2% avg
-75%
Cost per patient vs peers
$348 vs $1,411 avg
-9%
Brand preference vs peers
9.7% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
ML fraud detection score of 83% indicates prescribing patterns with significant similarity to confirmed fraud cases. 17 out of 20 decision trees flagged this provider.
Opioid rate is 324% above Internal Medicine peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
9.5%
Opioid Rate
836
Opioid Claims
$21K
Opioid Cost
10.3%
Long-Acting Rate
Brand vs Generic
Brand: 839 claims · $239K
Generic: 7,846 claims · $152K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Tiotropium Bromide | 56 | $40K |
| Dabigatran Etexilate Mesylate | 122 | $30K |
| Rivaroxaban | 33 | $27K |
| Apixaban | 34 | $22K |
| Semaglutide | 20 | $21K |
| Empagliflozin | 21 | $12K |
| Insulin Nph Human Isophane | 62 | $11K |
| Fluticasone Propion/Salmeterol | 39 | $9,380 |
| Atorvastatin Calcium | 563 | $8,571 |
| Hydrocodone/Acetaminophen | 338 | $7,257 |
| Ciclesonide | 52 | $6,833 |
| Insulin Nph Human Isophane | 18 | $4,812 |
| Oxycodone Hcl | 210 | $4,509 |
| Gabapentin | 130 | $4,281 |
| Lisinopril | 355 | $4,061 |
Prescribing Profile
Patient Profile
73
Avg Age
53%
Female
1.15
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data